ABX advanced biochemical compounds GmbH
ABX Advanced Biochemical Compounds GmbH, commonly referred to as ABX, is a leading player in the biochemical industry, headquartered in Germany. Founded in 1998, the company has established a strong presence in Europe and beyond, specialising in the development and production of high-quality biochemical compounds for research and diagnostics. ABX is renowned for its innovative range of products, including custom synthesis services and a diverse portfolio of reagents that cater to the needs of laboratories and research institutions. Their commitment to quality and precision sets them apart in a competitive market, making them a trusted partner for scientific advancement. With a focus on continuous improvement and customer satisfaction, ABX has achieved significant milestones, solidifying its position as a key contributor to the biochemical sector. The company’s dedication to excellence and innovation has earned it recognition and respect within the scientific community.
DitchCarbon Score
How does ABX advanced biochemical compounds GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ABX advanced biochemical compounds GmbH's score of 57 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ABX advanced biochemical compounds GmbH, headquartered in Germany, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Otsuka Pharmaceutical Co., Ltd., which influences its climate commitments and initiatives. While ABX does not have its own documented reduction targets, it inherits sustainability initiatives from its parent company, Otsuka Holdings Co., Ltd. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These initiatives are cascaded from Otsuka Pharmaceutical Co., Ltd. at a level 2 and Otsuka Holdings Co., Ltd. at a level 3, reflecting a structured approach to climate action within the corporate family. ABX's climate strategy aligns with broader industry standards, focusing on reducing greenhouse gas emissions and enhancing sustainability practices. However, specific reduction targets or achievements for ABX itself have not been disclosed. The company is expected to contribute to the overarching goals set by its parent organisation, which are aimed at fostering a more sustainable future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 101,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 159,000,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 866,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ABX advanced biochemical compounds GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
